KANSAS CITY, Kan. and BOSTON, Oct. 21, 2013 /PRNewswire/ -- Aratana Therapeutics , Inc. (Nasdaq: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, today announced that it has elected Merck & Co, Inc.'s former Chief Marketing Officer Wendy Yarno to its Board of Directors.
Jay Lichter, PhD, Aratana's Chairman of the Board, stated, "Ms. Yarno's impressive career at Merck and her deep board experience make her an excellent addition. We expect to benefit greatly from her expertise."
Ms. Yarno commented, "I'm excited to join Aratana's Board of Directors as it accelerates toward commercialization. I look forward to being part of a pioneering company that is bringing innovation from human medicine to pets."
Ms. Yarno held positions of increasing responsibility in multiple business groups during her career at Merck & Co, Inc. Most recently she served as Chief Marketing Officer, where she led the global organization responsible for supporting product commercialization across multiple therapeutic areas. At one point during her career, Ms. Yarno served as Merck's Senior Vice President of Human Resources. Ms. Yarno received an MBA from the Fox School of Business at Temple University and a B.S. in business administration from Portland State University. She also serves on the Board of Directors for St. Jude Medical, Medivation, ADial Pharmaceuticals, and PluroGen Therapeutics.About Aratana TherapeuticsAratana Therapeutics is a development-stage biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets, or pet therapeutics. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. Aratana's strategy is to in-license proprietary compounds from human biopharmaceutical companies and to develop these product candidates into therapeutics specifically for use in pets. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit www.aratana.com. Forward-Looking Statements DisclaimerThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the expansion of our commercial infrastructure; expectations regarding development programs, trials, studies, and approval; expectations regarding in-license initiatives; and expectations regarding the Company's plans and opportunities.